Drug recall · September 26, 2018
Lamotrigine Extended-Release Tablets recall
Why: Failed Dissolution Specifications: Out of Specification for Dissolution test (Buffer Stage) at the 5-hour time point during stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Lamotrigine Extended-Release Tablets, USP, 200 mg, 30 tablets per bottle, Rx Only, Manufactured in INDIA, For: TORRENT PHARMA INC., 150 Allen Road, Suite 102, Basking Ridge, NJ 07920. NDC: 13668-342-30
- Lots / codes
Lot: BFR5D002 EXP 11-2019
- Quantity
- 15,384 30-count bottles
- Company
- Torrent Pharma Inc., Kalamazoo, MI
- Distribution
- Nationwide USA
- Initiated
- September 11, 2018 · Voluntary: Firm initiated
- Classified
- September 20, 2018
- Reported
- September 26, 2018
- Ended
- September 4, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Lamotrigine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.